Related Experiment Video
Updated: Jun 17, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Inhalation adjuvant therapy for lung cancer.
Dandan Yi1, Timothy Scott Wiedmann
1University of Minnesota, Department of Pharmaceutics, Minneapolis, Minnesota 55455, USA.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|January 16, 2010
Summary
Inhaling chemotherapy for Stage II nonsmall-cell lung cancer (NSCLC) and chemopreventive agents for Stage I lung adenocarcinomas offers a novel approach to improve lung cancer treatment and demonstrates the potential of inhalation therapy.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Lung cancer is a leading cause of cancer death globally.
- Nonsmall-cell lung cancer (NSCLC) is the most common type, with adenocarcinomas and squamous cell carcinomas as subtypes.
- Current treatments for lung cancer have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To explore the potential of inhalation therapy for lung cancer treatment.
- To evaluate the efficacy of inhaled chemotherapy as an adjuvant therapy for Stage II NSCLC.
- To investigate the use of inhaled chemopreventive agents for Stage I lung adenocarcinomas.
Main Methods:
- A comprehensive literature review was conducted.
- The review focused on studies related to adjuvant therapy for lung cancer.
- The review also examined literature on inhalation chemoprevention for lung cancer.
Main Results:
- Inhalation chemotherapy is proposed as an adjuvant treatment for Stage II NSCLC.
- Inhalation of chemopreventive agents is suggested for Stage I lung adenocarcinomas.
- These inhalation approaches may significantly improve lung cancer therapy outcomes.
Conclusions:
- Inhalation therapy presents a promising direct route to enhance lung cancer treatment.
- Successful implementation could extend to treating other lung cancer types.
- This strategy highlights the utility of inhalation delivery in oncology.
Related Concept Videos
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.